A Study to Determine the Efficacy and Safety of 2 Doses of Org 34517 as Adjunctive Therapy in Subjects With Psychotic Major Depression (28130)(P05845) (Hermes)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00212797
Recruitment Status : Completed
First Posted : September 21, 2005
Last Update Posted : November 26, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The primary purpose of this study is to determine whether subjects with psychotic major depression benefit from adjunctive treatment with Org 34517. Two doses of Org 34517 will be compared to placebo in this international multicenter study. The duration of this trial is 6 weeks.

Condition or disease Intervention/treatment Phase
Depression Depressive Disorders Psychotic Disorders Drug: Org 34517 Drug: Placebo Phase 2

Detailed Description:

Major depression with psychotic features (psychotic depression) is the most debilitating disorder in the depressive disorders spectrum. It is associated with severe symptoms, prolonged course, poorer response rates, more residual symptoms, more frequent relapses and higher mortality, as compared to major depressive disorder.

The markedly abnormal HPA axis functioning in psychotic depression has encouraged research to investigate whether the HPA axis would be a target for pharmacotherapy in depression.

The primary purpose of this study is to determine whether subjects with psychotic major depression benefit from adjunctive treatment with GR antagonist Org 34517. Two doses of Org 34517 will be compared to placebo in this international multicenter study. The duration of this trial is 6 weeks.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 273 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Prospective, Double-Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunctive Therapy in Subjects With Psychotic Major Depression (Major Depressive Episode, Severe, With Psychotic Features).
Study Start Date : July 2004
Actual Primary Completion Date : July 2006
Actual Study Completion Date : July 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Org 34517_1
low dose Org 34517
Drug: Org 34517
low dose Org 34517
Experimental: Org 34517_2
high dose Org 34517
Drug: Org 34517
high dose Org 34517
Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. PANSS positive symptoms subscale. [ Time Frame: 6 weeks ]

Secondary Outcome Measures :
  1. Ham-D17, CGI, Cognition, spermatogenesis [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • have provided voluntary written informed consent for trial participation after the scope and nature of the investigation were explained to them, and before starting any trial-related activities (before Screening);
  • be able to speak, read, understand, respond to questions, and follow

instructions in English or their native language;

  • have DSM-IV severe depressive episode with psychotic features, as

diagnosed by the MINI for single or recurrent episodes (296.24 or 296.34);

have a score on PANSS item "Delusions" AND/OR "Hallucinatory behavior" of at least 4 at Screening and Baseline;

  • have a PANSS Positive Scale score of at least 16 at Screening and Baseline;
  • have a total score of at least 18 on the HAMD 17-item scale at Screening and Baseline;
  • be on a stable dose of "usual treatment", which had to consist of an

antidepressant, an antipsychotic, a mood stabilizer or any combination of these 3 drug classes;

  • be between 18 and 75 years of age (inclusive) at Screening;
  • be willing to be hospitalized for at least 11 days from Screening onwards.

Exclusion Criteria:

  • have any other current psychiatric diagnosis (according to the MINI) except MDD, such as organic mental syndromes and disorders, delirium or anxiety disorders;
  • have a lifetime psychiatric diagnosis of psychotic disorders (according to the MINI), or a MINI diagnosis of past manic episode;
  • be at significant risk of committing suicide, as indicated by a score greater than 9 on the revised InterSePT Scale for Suicidal Thinking (ISST);
  • be currently treated with carbamazepine or valproate;
  • be currently treated with midazolam;
  • be treated with electroconvulsive therapy in the current episode;
  • be currently treated with more than one antidepressant;
  • be currently treated with more than one antipsychotic;
  • be currently treated with more than one mood stabilizer;
  • have a "usual treatment" started or discontinued in the 2 weeks before


  • have a "usual treatment" dose change within the week prior to


  • have any clinically unstable or uncontrollable renal, hepatic, respiratory,

hematological, cardiovascular or cerebrovascular disease that would put the patient at risk of safety or bias assessment of efficacy;

have known hypersensitivity reactions to glucocorticoid antagonists;

  • have any clinically significant abnormal laboratory data (e.g. aspartate amino transferase (ASAT) and/or alanine amino transferase (ALAT) values > 2x normal range upper limit) or ECG results, or a clinically significant abnormal outcome at the physical examination at the screening visit;
  • have any untreated or uncompensated clinically significant endocrine


  • have a MINI diagnosis of alcohol and/or drug dependence;
  • have a confirmed positive result on the drug screening test for any illicit drug, except cannabis, at Screening;
  • be using hormone replacement therapy at Screening;
  • have required concomitant treatment with corticosteroids, like

dexamethasone, prednisone or cortisol (topical use is allowed);

  • be diagnosed with Cushing's disease;
  • be women of childbearing potential without adequate contraception;
  • be women with a positive pregnancy test at Screening or Baseline, or

breastfeeding mothers;

  • be males with a current diagnosis of prostate hypertrophia or past history (less than 3 months) of symptoms of prostate hypertrophia.
  • be currently treated with clozapine (per Amendment III);
  • be currently treated with systemic or topical ketaconazole.

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00212797     History of Changes
Other Study ID Numbers: P05845
Protocol 28130
First Posted: September 21, 2005    Key Record Dates
Last Update Posted: November 26, 2015
Last Verified: November 2015

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Mental Disorders
Psychotic Disorders
Pathologic Processes
Behavioral Symptoms
Mood Disorders
Schizophrenia Spectrum and Other Psychotic Disorders